Further evidence for pathogenicity of the TP53 tetramerization domain mutation p.Arg342Pro in Li–Fraumeni syndrome
In conclusion, we provide evidence for the co-segregation of a TP53 tetramerization domain mutation and cancer phenotypes, but also report pre-symptomatic mutation carriers within the family. We review published recommendations for clinical management and surveillance of high-risk members in Li–Fraumeni kindreds.
Source: Familial Cancer - Category: Cancer & Oncology Source Type: research
More News: Adrenocortical Carcinoma | Bone Cancers | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Children | Genetics | Leukemia | Lung Cancer | Osteosarcoma | Sarcomas